Fall 2021 Newsletter

Fall 2021 Newsletter

  1. Home
  2. Newsletters
  3. Fall 2021 Newsletter

A Note from the President

It’s hard to believe that December is already here! Looking back on 2021, it was truly a stellar year for TransPharm Preclinical Solutions. Many businesses are still feeling the economic impacts of the pandemic, but TransPharm has been able to rebound thanks to our fantastic clients. We appreciate you!

TransPharm will close for winter break around 12pm EST on December 24, 2021 and we will return the morning of January 3, 2022. We wish you a happy holiday season and look forward to working with you in the new year!


Daniel Ross
President & CEO

In the Lab

New Preclinical Model: Diabetic Wound

TransPharm has now validated our dermal infection – deep wound model in mice with streptozotocin (STZ)-induced type 1 diabetes. A biopsy punch is used to create a full-thickness, 6 mm wound over the thoracic spine area on the dorsal surface, and then C. albicans is introduced to the wound to initiate a fungal infection. Test articles are administered topically and endpoints include photographs of the healing process and/or skin harvests.

Contact us today for more information or to request a free, no-obligation quote for your diabetic wound study.


Santiago R. Lopez, Ph.D.
Chief Scientific Officer

Welcome McKenzie!

This summer, McKenzie Mahlmeister joined TransPharm as an Associate Scientist. She received her Bachelor’s degree in Animal Science and Biology in 2016 from the University of Findlay (UF) in Findlay, Ohio. While at UF, she competed on the cross country and track teams. After graduation, McKenzie worked on a farm and at the University of Michigan as an animal care technician. She received her RLAT certification in 2019. Welcome McKenzie! We are excited to have you on our team.



Contact Us

1 + 6 =

Jackson Certified
Brooklyn-Irish Hills Chamber of Commerce logo

science exchange logo

scientist.com logo